# Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn

> **NCT02261883** · PHASE2 · TERMINATED · sponsor: **United Therapeutics** · enrollment: 42 (actual)

## Conditions studied

- Persistent Pulmonary Hypertension of the Newborn

## Interventions

- **DRUG:** IV Remodulin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02261883
- **Lead sponsor:** United Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-07-29
- **Primary completion:** 2022-09-27
- **Final completion:** 2023-05-17
- **Target enrollment:** 42 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2024-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02261883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02261883, "Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02261883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*